BOCA RATON, Fla., March 3 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals announced today that Thomas H. McLain, chairman, chief executive officer and president, will be presenting at the Lehman Brothers Ninth Annual Global Healthcare Conference on March 9, 2006, at 8:30 am ET at the Loews Miami Beach Hotel, Poinciana 4 Room, 1601 Collins Avenue, Miami Beach, Florida. Mr. McLain will present a company overview, and Henrik Rasmussen, M.D., Ph.D., senior vice president, clinical, medical and regulatory affairs, will speak about Civacir(R) [Hepatitis C Immune Globulin (Human)], the company’s investigational human polyclonal antibody product that contains antibodies to hepatitis C virus (HCV). Civacir is being developed to prevent hepatitis C disease in HCV-positive liver transplant patients and is being evaluated for the treatment of chronic hepatitis C virus infections. Civacir has received Orphan Drug Designation from the U.S. Food and Drug Administration.
The presentation will be webcast live at: http://customer.talkpoint.com/LEHM002/030806a_cs/default.asp?entity=Nabi
The webcast presentation will be available through April 3, 2006.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. The company has three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) (allopurinol sodium) for Injection. Nabi Biopharmaceuticals is focused on developing products that address unmet medical needs and offer commercial opportunities in our core business areas: Gram-positive bacterial infections, hepatitis, kidney disease (nephrology) and nicotine addiction. For a complete list of pipeline products, please go to http://www.nabi.com/pipeline/index.php . The company is headquartered in Boca Raton, Florida. For additional information about Nabi Biopharmaceuticals, please visit our website at http://www.nabi.com .
Audio: http://customer.talkpoint.com/LEHM002/030806a_cs/default.asp?entity=NabiNabi Biopharmaceuticals
CONTACT: Tom Rathjen, Vice President, Investor Relations, NabiBiopharmaceuticals, +1-561-989-5800
